199 Female sex and mortality in SAB 9 Outcome Despite differences in clinical presentation and management of SAB in women and men, no significant differences were noted in 90-day mortality in either univariable (388/1431 [27%] in women vs. 491/1953 [25%] in men, p 0.204, Table 1) or multivariable analysis (adjusted hazard ratio for women 0.98, 95% CI, 0.85-1.13, Figure 1). Thirty-day mortality was also similar in women and men (301/1431 [21%] in women vs. 381/1953 [20%] in men, p 0.278). In the patients who died within 90 days, the median time from first positive blood culture to death was similar in both sexes (median 13 [IQR 5-27] days in women vs. 12 [IQR 4-28] days in men, p 0.346, Figure 2). When stratified for MSSA versus MRSA, no difference in mortality between sexes was found in either group (Table S3). Furthermore, no significant differences in mortality between women and men were noted across study time periods (19942002; 2003-2011; 2012-2020, Table S4) or when analyses were stratified by route of acquisition (community-acquired, healthcare-associated or hospital-acquired SAB; Table S5). Fig. 1. Forest plot with adjusted hazard ratios for 90-day mortality in patients with S. aureus bacteraemia. aHR, adjusted hazard ratio; APS, acute physiology score at time of first positive blood culture; MRSA, methicillin-resistant Staphylococcus aureus; TEE, transesophageal echocardiography. aReference: MSSA bacteraemia treated with cefazolin or antistaphylococcalpenicillin. bReference: white race. cReference: community-acquired.
RkJQdWJsaXNoZXIy MTk4NDMw